Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

NCT07659782 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT07659782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07659782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
Lead sponsor
Verastem, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 22, 2026
Completion date
December 31, 2028
Enrollment
105 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer